capecitabine and oxaliplatin

Phase 3Small molecule

capecitabine and oxaliplatin is one of 182 small molecule programs targeting Colorectal Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

181

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal CarcinomaActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Biliary Tract CancerActive, not recruiting

Breast CancerActive, not recruiting

Colorectal CancerActive, not recruiting

Gastric CancerActive, not recruiting

Colorectal CarcinomaPreclinical

Active, not recruiting

Metastatic Colorectal CancerPhase 2

Active, not recruiting

Biliary Tract CancerPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Colorectal CancerPhase 2/Phase 3

Active, not recruiting

Gastric CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

capecitabine and oxaliplatin

FFudan University

Phase 3

1 2

Halaven

Eisai

Preclinical

38 3

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 4

Gemzar

GGynecologic Oncology Group

Preclinical

22 5

Zolymbus

AbbVie

Preclinical

1 6

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 8

Spravato

WWim Janssens

Preclinical

2 9

Chantix

PPrism Pharmaceuticals

Preclinical

1 10

Tricor

JJagotec

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Recruiting

Gastric Cancer

NCT01935778

Clinical

Trials by Indication[1]

Gastric Cancer2 trials

Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory Gastric Cancer

Suspended·FFudan University·Phase 2·NCT00568529·30 enrolled

Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH

Recruiting·—·Phase 3·NCT01935778·286 enrolled

Metastatic Colorectal Cancer1 trial

Capecitabine and Oxaliplatin With or Without Cetuximab in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery

Completed·SSwiss Cancer Institute·Phase 2·NCT00227734·74 enrolled

Biliary Tract Cancer1 trial

Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer

Completed·SSwiss Cancer Institute·Phase 2·NCT00073905·44 enrolled

Colorectal Cancer1 trial

Combination Chemotherapy Treatments in Patients With Colorectal Cancer Stage II and III

Unknown status·SState Key Laboratory of Cancer Biology·Phase 2/3·NCT01196260·8,000 enrolled

Colorectal Carcinoma1 trial

Comparison of Efficacy and Safety Between FOLFOX-6 and CAPOX in Metastatic Colorectal Carcinoma

Enrolling by invitation·—·N/A·NCT07334587·248 enrolled

2 more indications

Breast Cancer1 trial

XELOX for Metastatic Breast Cancer

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT00204776·37 enrolled

Circulating Tumor Cells1 trial

Detection and Enumeration of Circulating Tumor Cells in Rectal Cancer

Unknown status·FFudan University··NCT01671891·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for capecitabine and oxaliplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — capecitabine and oxaliplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for capecitabine and oxaliplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fudan University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FFudan University

capecitabine and oxaliplatin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Gastric Cancer2 trials

Metastatic Colorectal Cancer1 trial

Biliary Tract Cancer1 trial

Colorectal Cancer1 trial

Colorectal Carcinoma1 trial

Breast Cancer1 trial

Circulating Tumor Cells1 trial

References

Drug Info

Quick Facts

Related News